[43] reported that the combined treatment of interleukin-6 receptor (IL-6R) inhibitor and low-dose TKI inhibitor was more effective in inhibiting RCC growth and angiogenesis in vivo compared with the use of TKI inhibitor alone. This evidence concerns the gene IL6R and renal cell carcinoma.